- Home
- RY vs GILD Comparison
RY vs GILD Comparison
Compare RY & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RY
- GILD
- Stock Information
- Founded
- RY 1864
- GILD 1987
- Country
- RY Canada
- GILD United States
- Employees
- RY N/A
- GILD N/A
- Industry
- RY
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RY
- GILD Health Care
- Exchange
- RY Nasdaq
- GILD Nasdaq
- Market Cap
- RY 159.6B
- GILD 129.9B
- IPO Year
- RY N/A
- GILD 1992
- Fundamental
- Price
- RY $120.38
- GILD $97.97
- Analyst Decision
- RY Strong Buy
- GILD Buy
- Analyst Count
- RY 2
- GILD 26
- Target Price
- RY $156.50
- GILD $108.00
- AVG Volume (30 Days)
- RY 1.2M
- GILD 8.7M
- Earning Date
- RY 05-29-2025
- GILD 04-24-2025
- Dividend Yield
- RY 3.43%
- GILD 3.22%
- EPS Growth
- RY 16.08
- GILD 1118.07
- EPS
- RY 8.49
- GILD 4.73
- Revenue
- RY $39,472,538,730.00
- GILD $28,735,000,000.00
- Revenue This Year
- RY $22.14
- GILD $1.88
- Revenue Next Year
- RY $3.42
- GILD $3.95
- P/E Ratio
- RY $14.11
- GILD $20.75
- Revenue Growth
- RY 16.96
- GILD 4.68
- 52 Week Low
- RY $101.96
- GILD $62.07
- 52 Week High
- RY $128.05
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- RY 60.88
- GILD 36.07
- Support Level
- RY $119.59
- GILD $95.30
- Resistance Level
- RY $121.21
- GILD $107.17
- Average True Range (ATR)
- RY 1.43
- GILD 3.59
- MACD
- RY 0.15
- GILD -0.66
- Stochastic Oscillator
- RY 78.64
- GILD 32.38
About RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with over CAD 2 trillion in assets. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).